Joining the annual APMA 2021 Annual Scientific Meeting held from July 29 to August 1, was an important opportunity to share Hexima’s data on pezadeftide’s potential in the management of onychomycosis and discuss with leading physicians in this specialty. In the US, Podiatrists tend to manage most cases of onychomycosis and importantly write 80% of all prescriptions for onychomycosis.
Hexima CEO Michael Aldridge commented, “Presenting at the APMA meeting provides a valuable opportunity to highlight the impressive safety and efficacy data we have seen from Hexima’s phase I/IIa clinical study and to discuss the significant potential of pezadeftide with this important group of future prescribers as we ensure the development of pezadeftide effectively meets the needs of patients with onychomycosis.”
Alongside the APMA meeting, Hexima held an investor webinar at 9 am AEST 29 July 2021 to review the data presented.
You can view the webinar here → Webinar
Or see the poster in full here → Poster